| Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer’s disease: In vitro and in vivo studies AH Abuznait, H Qosa, BA Busnena, KA El Sayed, A Kaddoumi ACS chemical neuroscience 4 (6), 973-982, 2013 | 330 | 2013 |
| Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders H Qosa, DS Miller, P Pasinelli, D Trotti Brain research 1628, 298-316, 2015 | 262 | 2015 |
| Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease H Qosa, AH Abuznait, RA Hill, A Kaddoumi Journal of Alzheimer's Disease 31 (1), 151-165, 2012 | 209 | 2012 |
| Differences in amyloid-β clearance across mouse and human blood–brain barrier models: kinetic analysis and mechanistic modeling H Qosa, BS Abuasal, IA Romero, B Weksler, PO Couraud, JN Keller, ... Neuropharmacology 79, 668-678, 2014 | 162 | 2014 |
| Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model H Qosa, YS Batarseh, MM Mohyeldin, KA El Sayed, JN Keller, ... ACS chemical neuroscience 6 (11), 1849-1859, 2015 | 158 | 2015 |
| Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the brains of TgSwDI mice H Qosa, LA Mohamed, YS Batarseh, S Alqahtani, B Ibrahim, H LeVine III, ... The Journal of Nutritional Biochemistry 26 (12), 1479-1490, 2015 | 115 | 2015 |
| Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P‐Glycoprotein) in endothelial cells of the blood–brain barrier in mutant superoxide dismutase 1 … H Qosa, J Lichter, M Sarlo, SS Markandaiah, K McAvoy, JP Richard, ... Glia 64 (8), 1298-1313, 2016 | 77 | 2016 |
| Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population AM Yousef, NR Bulatova, W Newman, N Hakooz, S Ismail, H Qusa, ... Molecular biology reports 39, 9423-9433, 2012 | 74 | 2012 |
| FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation ED Pulte, KJ Norsworthy, Y Wang, Q Xu, H Qosa, R Gudi, D Przepiorka, ... Clinical cancer research 27 (13), 3515-3521, 2021 | 73 | 2021 |
| Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood–brain … H Qosa, H LeVine III, JN Keller, A Kaddoumi Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1842 (9 …, 2014 | 70 | 2014 |
| Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastigmine in rats LA Mohamed, H Qosa, A Kaddoumi ACS chemical neuroscience 6 (5), 725-736, 2015 | 64 | 2015 |
| High-throughput screening for identification of blood-brain barrier integrity enhancers: a drug repurposing opportunity to rectify vascular amyloid toxicity H Qosa, LA Mohamed, SB Al Rihani, YS Batarseh, QV Duong, JN Keller, ... Journal of Alzheimer’s Disease 53 (4), 1499-1516, 2016 | 60 | 2016 |
| Comparison of the intestinal absorption and bioavailability of γ‐tocotrienol and α‐tocopherol: in vitro, in situ and in vivo studies BS Abuasal, H Qosa, PW Sylvester, A Kaddoumi Biopharmaceutics & drug disposition 33 (5), 246-256, 2012 | 52 | 2012 |
| FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma EC Nakajima, PJ Vellanki, E Larkins, S Chatterjee, PS Mishra-Kalyani, ... Clinical cancer research 28 (3), 446-451, 2022 | 48 | 2022 |
| Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products AH Abuznait, H Qosa, ND O’Connell, J Akbarian-Tefaghi, PW Sylvester, ... Food and Chemical Toxicology 49 (11), 2765-2772, 2011 | 45 | 2011 |
| In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia H Qosa, BR Avaritt, NR Hartman, DA Volpe Cancer chemotherapy and pharmacology 82, 795-802, 2018 | 40 | 2018 |
| Transporters as drug targets in neurological diseases H Qosa, LA Mohamed, S Alqahtani, BS Abuasal, RA Hill, A Kaddoumi Clinical Pharmacology & Therapeutics 100 (5), 441-453, 2016 | 37 | 2016 |
| Orlistat limits cholesterol intestinal absorption by Niemann-pick C1-like 1 (NPC1L1) inhibition S Alqahtani, H Qosa, B Primeaux, A Kaddoumi European journal of pharmacology 762, 263-269, 2015 | 35 | 2015 |
| Adverse effects of tacrolimus in renal transplant patients from living donors N Bulatova, AM Yousef, G Al-Khayyat, H Qosa Current drug safety 6 (1), 3-11, 2011 | 34 | 2011 |
| Effect of mouse strain as a background for Alzheimer’s disease models on the clearance of amyloid-β H Qosa, A Kaddoumi Journal of systems and integrative neuroscience 2 (2), 135, 2016 | 22 | 2016 |
